News

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Str

On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]

Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward.

The signs were not in the headline growth rate but in which two products were trading places.

Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.

Regulatory acceptance opens the door, but it neither guarantees approval nor repairs Novo's late start.

The FDA approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes.

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

Eli Lilly Stock Eyes New Upside After FDA Expands Mounjaro Approval

The FDA decision expands Mounjaro beyond glucose control while strengthening its position against competing cardiovascular therapies.

Eli Lilly trades at $1,175 per share and has stayed right on track with the overall market, gaining 15.4% over the last six months. At the same time, the S&P 500 has returned 11.6%.

ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.

Lilly just strengthened one of its biggest growth engines

A new FDA approval extends Lilly's blockbuster into cardiovascular risk reduction

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively trad

Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Lilly’s diabetes drug Trulicity.

Outpacing the Dow over the past 12 months, Eli Lilly continues to receive a highly bullish outlook from Wall Street analysts, reflecting confidence in the company’s long-term prospects.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

Regulatory acceptance expands Novo's addressable market, but Lilly filed first and may launch its competing pill sooner.

China's drug regulator accepted Novo Nordisk's application for an oral version of Wegovy as the Danish company competes with Eli Lilly in the market

The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.

Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker’s ability to return to growth and navigate an impending patent cliff.

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

The company now leads with a cost-savings total and a growth rate that does not begin until the end of the decade, which tells a holder far less about whether its medicines are winning.

The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.

LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.